Literature DB >> 3042872

Immunization with rough mutants of Salmonella minnesota: initial studies in human subjects.

A DeMaria1, M A Johns, H Berberich, W R McCabe.   

Abstract

Vaccines prepared from unheated and boiled, acetone-precipitated Salmonella minnesota R595 (Re chemotype mutant) were administered subcutaneously to 122 healthy volunteers. Titers of antibody to Re lipopolysaccharide, the basal core structure of endotoxin, as measured by indirect hemagglutination, rose in a dose-responsive fashion after immunization. Febrile reactions, usually mild, occurred after 7% of injections with the highest doses (2.0 and 3.0 x 10(10) organisms), and mild local soreness and tenderness were noted after approximately one-third of injections. Passive immunization of mice with sera from immunized subjects demonstrated that protective activity against challenge with both heterologous, viable gram-negative bacilli and endotoxin developed. Although measuring serum protective activity, developing a serological assay that correlates with protective activity, and potential vaccine toxicity remain problems, immunization of humans with the Re mutant results in serum protective activity against endotoxin and viable bacilli and has the potential for clinical usefulness.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3042872     DOI: 10.1093/infdis/158.2.301

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

1.  Characterization of the epitope specificity of murine monoclonal antibodies directed against lipid A.

Authors:  H M Kuhn; L Brade; B J Appelmelk; S Kusumoto; E T Rietschel; H Brade
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

2.  Synthesis, characterization, and immunological properties in mice of conjugates composed of detoxified lipopolysaccharide of Salmonella paratyphi A bound to tetanus toxoid with emphasis on the role of O acetyls.

Authors:  E Konadu; J Shiloach; D A Bryla; J B Robbins; S C Szu
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

3.  Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin.

Authors:  R K Gupta; S C Szu; R A Finkelstein; J B Robbins
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

Review 4.  Immunoprophylaxis and immunotherapy of gram-negative sepsis and shock with antibodies to core glycolipids and lipid A of bacterial lipopolysaccharides.

Authors:  I G Mitov; D G Terziiski
Journal:  Infection       Date:  1991 Nov-Dec       Impact factor: 3.553

5.  Phase 1 testing of detoxified LPS/group B meningococcal outer membrane protein vaccine with and without synthetic CPG 7909 adjuvant for the prevention and treatment of sepsis.

Authors:  Alan S Cross; Nancy Greenberg; Melissa Billington; Lei Zhang; Christopher DeFilippi; Ryan C May; Kanwaldeep K Bajwa
Journal:  Vaccine       Date:  2015-10-26       Impact factor: 3.641

6.  Phase 1 and phase 2 studies of Salmonella enterica serovar paratyphi A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam.

Authors:  E Y Konadu; F Y Lin; V A Hó; N T Thuy; P Van Bay; T C Thanh; H B Khiem; D D Trach; A B Karpas; J Li; D A Bryla; J B Robbins; S C Szu
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

7.  alpha-GlcNAc-1-->2-alpha-glc, the Salmonella homologue of a conserved lipopolysaccharide motif in the Enterobacteriaceae, elicits broadly cross-reactive antibodies.

Authors:  N A Nnalue
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

8.  Comparative immunogenicity of conjugates composed of Escherichia coli O111 O-specific polysaccharide, prepared by treatment with acetic acid or hydrazine, bound to tetanus toxoid by two synthetic schemes.

Authors:  R K Gupta; W Egan; D A Bryla; J B Robbins; S C Szu
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

9.  Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids.

Authors:  D N Taylor; A C Trofa; J Sadoff; C Chu; D Bryla; J Shiloach; D Cohen; S Ashkenazi; Y Lerman; W Egan
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

10.  Sequential anti-core glycolipid immunoglobulin antibody activities in patients with and without septic shock and their relation to outcome.

Authors:  M Nys; P Damas; L Joassin; M Lamy
Journal:  Ann Surg       Date:  1993-03       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.